Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions

Last Issue, we reported the publication of a small (N=19), open-label trial of LSD microdosing for major depressive disorder (MDD) that saw a 59.5% reduction in MADRS scores, which the authors said was sustained for up to six months. The Phase 2b results from the same program, sponsored by MindBio, were forthcoming. Well, now we have a topline readout from that Phase 2b (N=89) study…

Source